|
US7037922B1
(en)
*
|
2000-03-10 |
2006-05-02 |
Neurogen Corporation |
Aryl fused 2,4-disubstituted pyridines: NK3 receptor ligands
|
|
DE60004654T2
(de)
|
1999-03-29 |
2004-06-24 |
Neurogen Corp., Branford |
4-substituierte chinolinderivate als nk-3 und/oder gaba(a) rezeptor liganden
|
|
JP2003502314A
(ja)
*
|
1999-06-14 |
2003-01-21 |
イーライ・リリー・アンド・カンパニー |
化合物
|
|
BR0014843A
(pt)
|
1999-10-19 |
2002-06-11 |
Merck & Co Inc |
Composto, composição farmacêutica, métodos para tratar ou prevenir o câncer em um mamìfero, uma doença em que a angiogênese está implicada, a vascularização retinal, a retinipatia diabética, a degeneração macular relacionada com a idade, doença inflamatória, uma doença ou condição dependente de tirosina quinase e, patologias relacionadas com o osso, processo para fabricar uma composição farmacêutica, e, método para reduzir ou impedir o dano de tecido que segue um evento isquêmico
|
|
US6794393B1
(en)
|
1999-10-19 |
2004-09-21 |
Merck & Co., Inc. |
Tyrosine kinase inhibitors
|
|
US6420382B2
(en)
|
2000-02-25 |
2002-07-16 |
Merck & Co., Inc. |
Tyrosine kinase inhibitors
|
|
US6313138B1
(en)
|
2000-02-25 |
2001-11-06 |
Merck & Co., Inc. |
Tyrosine kinase inhibitors
|
|
US6521618B2
(en)
|
2000-03-28 |
2003-02-18 |
Wyeth |
3-cyanoquinolines, 3-cyano-1,6-naphthyridines, and 3-cyano-1,7-naphthyridines as protein kinase inhibitors
|
|
DE60113286T2
(de)
|
2000-10-17 |
2006-06-22 |
Merck & Co., Inc. |
Oral aktive salze mit tyrosinkinaseaktivität
|
|
GB0028964D0
(en)
*
|
2000-11-28 |
2001-01-10 |
Smithkline Beecham Spa |
Novel compounds
|
|
WO2003037252A2
(en)
|
2001-10-30 |
2003-05-08 |
Merck & Co., Inc. |
Tyrosine kinase inhibitors
|
|
CA2493854A1
(en)
*
|
2002-06-26 |
2004-01-08 |
Kyowa Hakko Kogyo Co., Ltd. |
Phosphodiesterase inhibitor
|
|
DE602004007105T2
(de)
|
2003-01-28 |
2008-02-28 |
Microbia Inc., Cambridge |
Zusammensetzung zur behandlung von gastrointestinalen störungen
|
|
US7772188B2
(en)
|
2003-01-28 |
2010-08-10 |
Ironwood Pharmaceuticals, Inc. |
Methods and compositions for the treatment of gastrointestinal disorders
|
|
RU2229475C1
(ru)
*
|
2003-03-06 |
2004-05-27 |
ООО "Исследовательский институт химического разнообразия |
6-сульфамоилхинолин-4-карбоновые кислоты, их производные и комбинаторная библиотека
|
|
TW201018662A
(en)
|
2005-12-12 |
2010-05-16 |
Astrazeneca Ab |
Alkylsulphonamide quinolines
|
|
US8969514B2
(en)
|
2007-06-04 |
2015-03-03 |
Synergy Pharmaceuticals, Inc. |
Agonists of guanylate cyclase useful for the treatment of hypercholesterolemia, atherosclerosis, coronary heart disease, gallstone, obesity and other cardiovascular diseases
|
|
ES2393885T7
(es)
|
2007-06-04 |
2014-01-30 |
Synergy Pharmaceuticals Inc. |
Agonistas de la guanilato ciclasa útiles para el tratamiento de trastornos gastrointestinales, inflamación, cáncer y otros trastornos
|
|
WO2008154207A1
(en)
*
|
2007-06-08 |
2008-12-18 |
The Burnham Institute For Medical Research |
Methods and compounds for regulating apoptosis
|
|
WO2009149279A2
(en)
|
2008-06-04 |
2009-12-10 |
Synergy Pharmaceuticals Inc. |
Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders
|
|
AU2009270833B2
(en)
|
2008-07-16 |
2015-02-19 |
Bausch Health Ireland Limited |
Agonists of guanylate cyclase useful for the treatment of gastrointestinal, inflammation, cancer and other disorders
|
|
WO2018129556A1
(en)
|
2017-01-09 |
2018-07-12 |
Ardelyx, Inc. |
Compounds and methods for inhibiting nhe-mediated antiport in the treatment of disorders associated with fluid retention or salt overload and gastrointestinal tract disorders
|
|
EP3351248B1
(en)
|
2008-12-31 |
2021-06-09 |
Ardelyx, Inc. |
Compounds and methods for inhibiting nhe-mediated antiport in the treatment of disorders associated with fluid retention or salt overload and gastrointestinal tract disorders
|
|
US9616097B2
(en)
|
2010-09-15 |
2017-04-11 |
Synergy Pharmaceuticals, Inc. |
Formulations of guanylate cyclase C agonists and methods of use
|
|
US10376481B2
(en)
|
2012-08-21 |
2019-08-13 |
Ardelyx, Inc. |
Compounds and methods for inhibiting NHE-mediated antiport in the treatment of disorders associated with fluid retention or salt overload and gastrointestinal tract disorders
|
|
CA2880338A1
(en)
|
2012-08-21 |
2014-02-27 |
Ardelyx, Inc. |
Compounds and methods for inhibiting nhe-mediated antiport in the treatment of disorders associated with fluid retention or salt overload and gastrointestinal tract disorders
|
|
US9486494B2
(en)
|
2013-03-15 |
2016-11-08 |
Synergy Pharmaceuticals, Inc. |
Compositions useful for the treatment of gastrointestinal disorders
|
|
WO2014151206A1
(en)
|
2013-03-15 |
2014-09-25 |
Synergy Pharmaceuticals Inc. |
Agonists of guanylate cyclase and their uses
|
|
KR102287207B1
(ko)
|
2013-04-12 |
2021-08-09 |
알데릭스, 인코포레이티드 |
Nhe3-결합 화합물 및 포스페이트 수송을 저해하는 방법
|
|
EP2986293A1
(en)
|
2013-04-19 |
2016-02-24 |
Astrazeneca AB |
A nk3 receptor antagonist compound (nk3ra) for use in a method for the treatment of polycystic ovary syndrome (pcos)
|
|
EP3004138B1
(en)
|
2013-06-05 |
2024-03-13 |
Bausch Health Ireland Limited |
Ultra-pure agonists of guanylate cyclase c, method of making and using same
|
|
JP6560335B2
(ja)
*
|
2014-07-08 |
2019-08-14 |
ダウ アグロサイエンシィズ エルエルシー |
３−ヒドロキシピコリン酸の製造方法
|
|
WO2017072629A1
(en)
|
2015-10-29 |
2017-05-04 |
Cadila Healthcare Limited |
Pharmaceutical combination of nk3 receptor antagonist and biguanides
|
|
JP2020505333A
(ja)
|
2017-01-09 |
2020-02-20 |
アルデリックス， インコーポレイテッド |
Ｎｈｅ媒介性アンチポートの阻害薬
|
|
CN110267944B
(zh)
|
2017-01-09 |
2024-03-08 |
阿德利克斯股份有限公司 |
可用于治疗胃肠道病症的化合物
|
|
EP3881843A4
(en)
*
|
2018-11-15 |
2022-08-03 |
Kyushu University, National University Corporation |
PROPHYLACTIC OR THERAPEUTIC AGENT AND MEDICINAL COMPOSITION FOR IL-31-MEDIATED DISEASE
|